NY Purpose: SCD is characterized by chronic organ dysfunction and poor quality of life (QOL). Myeloablative conditioning (MAC) and AlloSCT for SCD is the only curative therapy for children who are at high risk for SCD related morbidity and mortality (Bhatia et al, BMT, 2008). MAC and alloSCT are associated with significant acute morbidity and late effects (Satwani/Cairo et al, BBMT 2005). Despite the emerging clinical benefit of RTC alloSCT in SCD (Bhatia/Cairo et al, ASBMT, 2011), little is known about its impact on the longitudinal QOL of these patients. Therefore, the objective of this study was to serially evaluate the QOL of children who received RTC alloSCT for SCD. Methods: Hierarchical linear modeling was used to explore trends in PedsQL 4.0 physical, emotional, and social functioning sub-scales and select individual items of 14 children $ 5 years of age undergoing alloSCT for SCD between 2004 and 2008 at Columbia University Medical Center. QOL was assessed once pre-alloSCT and days 100, 180, 365, and 730, post-alloSCT. Post hoc exploratory analyses were performed to further evaluate the effect of RTC and alloSCT on outcomes. Effect sizes (ES) were included to describe the magnitude of difference in scores from baseline. Results: Mean age: 9.9 years. Emotional and social functioning was stable over time. Physical functioning (PF) was estimated to improve from baseline (BL) for parent (M 5 69.54) and child selfreport (M 5 72.96) at a rate of 0.57 (p 5 0.06) and 0.43 (p 5 0.16) points per month (ppm) respectively, with a large difference estimated at 2-years post-alloSCT by parent report (ES 5 0.93 SD) and a moderate difference by child self-report (ES 5 0.70 SD). Post hoc analysis of parent reported PF items revealed statistically significant improvements from BL in running, pain, and fatigue (Table 1) . A large ES difference was estimated for each of these items at 2-years post-alloSCT with running scoring 0.99 SD higher, pain improving by 1.72 SD, and fatigue by 1.31 SD. Children who received a matched related donor (MRD) transplant (M 5 69.05) significantly improved at a rate of 0.93 ppm/11.31 points per year (ppy) (t 5 3.08
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Thirty-one (74%) 2 nd D survivors continued to have BMDL: 16 (38%) osteopenic and 15 (36%) osteoporotic. Chronic GVHD and age had no association with T-score, osteoporosis or BMDL in this subset. Conclusions: There is a high prevalence of BMDL in allogeneic SCT survivors with a gradual trend towards improvement with time, influenced by age but not gender. Age and IST.3 are significantly associated with BMDL in the first decade. The loss of association with age and prolonged IST in the 2 nd D survivors implies that other factors may account for persistent BMDL in the 2 nd D. 
